ARISE 201 is the first double-blind, placebo-controlled, crossover, multicenter study of a drug (BTD-001) for the treatment of idiopathic hypersomnia (IH) and type 2 narcolepsy (T2N) in adults.

More than 20 study sites throughout the United States are currently prescreening or screening people with IH and T2N for enrollment, with some sites already having enrolled participants. Additional sites are on target to begin enrolling participants in the coming months.

If you are interested in finding out more about this study, please visit http://www.arisestudies.com/ or click on this link to the study on clinicaltrials.gov ( https://clinicaltrials.gov/ct2/show/NCT02512588 ).

Share Post